Johnson & Johnson (NYSE:JNJ – Get Free Report) posted its earnings results on Tuesday. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21, Briefing.com reports. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. During the same period last year, the company earned $2.66 EPS. The firm’s revenue was up 5.2% compared to the same quarter last year. Johnson & Johnson updated its FY 2024 guidance to 9.880-9.980 EPS and its FY24 guidance to $9.88-9.98 EPS.
Johnson & Johnson Stock Up 0.1 %
Shares of NYSE:JNJ opened at $164.28 on Thursday. The stock has a market cap of $395.37 billion, a P/E ratio of 10.24, a PEG ratio of 2.65 and a beta of 0.52. The company has a quick ratio of 0.85, a current ratio of 1.07 and a debt-to-equity ratio of 0.44. The business has a fifty day moving average of $162.81 and a two-hundred day moving average of $154.59. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85.
Johnson & Johnson Dividend Announcement
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on Johnson & Johnson
Insider Buying and Selling at Johnson & Johnson
In other news, VP Robert J. Decker sold 5,635 shares of Johnson & Johnson stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 0.16% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Further Reading
- Five stocks we like better than Johnson & Johnson
- What is Forex and How Does it Work?
- Should Warren Buffett’s Favorite Stock be Yours Too?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why Buffett Loves Occidental Stock And What It Means for Chevron
- Stock Dividend Cuts Happen Are You Ready?
- UnitedHealth Group Pulls Back Into a Healthy Buying Opportunity
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.